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series/8901.sequently, human‐to‐human transmission occurred toBackground
The Middle East respiratory syndrome coronavirus
(MERS‐CoV) is an emerging virus that may lead to
severe acute respiratory illness frequently associated with
multiorgan failure and death. The objective of this chap-
ter is to summarize the current state of knowledge
regarding the pathogenesis, clinical manifestations, diag-
nosis, management and outcomes of MERS‐CoV infec-
tion focusing on the critically ill.Epidemiology
The virus was first isolated from a patient with fatal
pneumonia and acute kidney injury in Jeddah, Saudi
Arabia in June 2012 [1]. After its identification, the virus
was linked to a healthcare‐associated cluster of re-
spiratory illnesses in Jordan dating back to March
2012 [2]. The disease epidemiology has been charac-
terized by sporadic cases throughout the year with
surges of cases occurring because of hospital out-
breaks. As of December 27, 2015, the World Health
Organization (WHO) had reported 1,621 laboratory‐
confirmed cases, including at least 584 (36 %) related
deaths [3]. Cases of MERS‐CoV have occurred in 26* Correspondence: arabi@ngha.med.sa
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© 2016 Al-Dorzi et al.countries, with all cases linked to residence in or
travel to the Arabian Peninsula.
The majority of cases have occurred in Saudi Arabia
(80 %) and South Korea (12 %) [3]. In Saudi Arabia,
multiple hospital outbreaks occurred in Alahsa (April–
May 2013) [4], Jeddah (April and May 2014) [5], and
Riyadh (August–September 2015) [3]. The outbreak in
the Republic of Korea started in May 2015 and resulted
from a case with travel history to the Middle East (Saudi
Arabia, Qatar, United Arab Emirates and Bahrain). Sub-
close contacts (family members, patients sharing a room
or ward with infected patients and healthcare workers
caring for infected patients) and led to 185 cases of
MERS‐CoV infection [3]. The last laboratory‐confirmed
case in Korea was on 4 July 2015 [3].Pathogenesis
Coronaviruses are a family of enveloped, single‐stranded
RNA viruses [6]. They can infect animals and humans
and have the propensity to cross species [6]. They cause
a variety of illnesses that range from the common cold
to severe respiratory illnesses [6]. The Severe Acute
Respiratory Syndrome coronavirus (SARS‐CoV) was the
first coronavirus identified to cause widespread out-
breaks of critical illness. It caused a worldwide outbreak
during the winter of 2002–2003, eventually leading to
8096 confirmed cases, including 774 deaths [7]. The
SARS epidemic was contained in 2003 [7]. SARS‐CoV
belongs to lineage B of the betacoronavirus [8], whereas
MERS‐CoV belongs to lineage C of the same genus.
MERS‐CoV enters cells via a common receptor, the
dipeptidyl peptidase‐4 (DPP4), also known as CD26, and
replicates in bronchial, bronchiolar and type I and II
alveolar epithelial cells [9, 10]. The virus has primarily
been detected in respiratory secretions, with the highest
viral loads in the lower respiratory tract [11]. In MERS‐
CoV cases, one study showed that approximately 70 % of
patients had continued respiratory shedding for > 30 days
[12]. MERS‐CoV infection often manifests with acute
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unknown, although direct viral infection is a possibility
since the DPP4 receptor is heavily expressed in human
kidneys [13]. Viral shedding has also been detected in
the urine and stool of infected patients [14].
There is accumulating evidence that camels are the
primary source for animal‐to‐human transmission of
MERS‐CoV. The virus has been isolated from dromedary
camels [15]. The high viral loads in the upper respiratory
tract of infected camels suggest that transmission to
humans occurs through close camel contact [15]. Trans-
mission through ingestion of camel products (meat and
milk) is possible but has never been confirmed. In a
cross‐sectional serosurveillance study of 10,009 individ-
uals in Saudi Arabia, positive serology was documented
in only 0.15 % [16]. Seropositivity was more common in
men than in women, in central than in coastal provinces
and in shepherds and slaughterhouse workers than in
others [16]. This may explain, at least in part, the
sporadic community‐acquired cases seen at low rates
throughout the year.
Human‐to‐human transmission of MERS‐CoV has
been demonstrated among close household contacts and
family members [17]. However, sustained community‐
based transmission has not been reported. Secondary
transmission within healthcare settings has been de-
scribed with already‐hospitalized patients and healthcare
workers acquiring the disease [18, 19]. This has been
attributed to overcrowding, movement of infected pa-
tients who did not yet have a diagnosis and breaches of
infection prevention and control practices [3]. A study
evaluated the stability of MERS‐CoV under different en-
vironmental conditions and found that the virus was
more stable at low temperature/low humidity than at
higher temperature/higher humidity conditions [20].
MERS‐CoV could be recovered after 48 h at a 20 °C/
40 % relative humidity condition [20]. During MERS‐
CoV aerosolization, no decrease in stability was observed
at the 20 °C/40 % relative humidity condition [20]. The
prolonged environmental presence suggests that MERS‐
CoV may be transmitted via contact or fomites [20],
although this has not been confirmed.
Clinical manifestations
The disease spectrum ranges from asymptomatic infec-
tion to rapidly progressive severe respiratory failure with
multiorgan failure. Symptomatic cases manifest after an
incubation period of 2–14 days [21]. Most severe cases
have been reported in adults with chronic comorbidities,
including diabetes mellitus, chronic cardiac disease,
chronic lung disease, end‐stage kidney disease, or
immunosuppression [21, 22]. However, severe infection
may also occur among younger patients, including
healthcare workers [18]. Compared with SARS‐CoV,MERS‐CoV affects older patients, men more than
women, and people with comorbid illnesses. The health-
care‐associated MERS‐CoV infections occurred within
the first week of the index case illness, while for SARS
they occurred mainly in the second week, likely due to
the different timings of peak viral load [23]. The current
literature suggests that children are rarely affected by
MERS‐CoV [24].
The most common clinical features in critically ill
patients with MERS‐CoV are fever (71 %), cough
(68 %), dyspnea (66 %), and gastrointestinal symptoms
(32 %) [21]. Common laboratory abnormalities include
leukopenia, lymphocytopenia, and thrombocytopenia,
elevated serum creatinine and lactate dehydrogenase,
and altered liver enzymes [21]. Initial chest radio-
graphs are abnormal in most symptomatic patients
and findings range from minimal abnormalities to ex-
tensive bilateral infiltrates [21]. Figure 1 shows the
chest radiographs of four patients with MERS‐CoV
pneumonia on the first day of intubation and demon-
strates different patterns of lung infiltrates. Computed
tomography (CT) findings have included bilateral air-
space opacities predominantly in the subpleural and
basilar lung regions with more extensive ground‐glass
opacities than consolidation [25].
Rapid progression to hypoxemic respiratory failure re-
quiring intubation usually occurs within the first week
after symptom onset [26]. In one observational study at
a single center in Saudi Arabia (October 1, 2012 to
May 31, 2014), severe infection requiring ICU admission
occurred in 49 (70 %) of 70 cases with 46 (66 %) requiring
invasive mechanical ventilation. In the univariate analysis,
factors associated with severe infection requiring ICU
admission were age ≥ 65 years (odds ratio [OR] 9.47,
95 % confidence interval [CI] 2.45–36.56), male sex
(OR 3.05, 95 % CI 1.05–8.84), higher age‐adjusted
Charlson comorbidity index (OR 1.35, 95 % CI 1.11–
1.65), the presence of bilateral pulmonary infiltrates
on chest radiograph (OR 4.89, 95 % CI 1.16–20.47),
concomitant infections (OR 12.66, 95 % CI 2.65–
60.46), and serum albumin < 35 g/l at MERS‐CoV
diagnosis (OR 8.0, 95 % CI 1.97–32.46) [19]. Severe neuro-
logic syndrome, including altered level of consciousness,
ranging from confusion to coma, ataxia, and focal motor
deficit, has been reported in three critically ill MERS‐CoV
patients, with brain magnetic resonance imaging (MRI)
showing widespread, bilateral hyperintense lesions on
T2‐weighted images in the white matter and subcor-
tical areas of different brain areas [27].
Diagnosis
The WHO has issued guidance for the definition of
MERS‐CoV cases, based on clinical criteria, exposure
history and diagnostic findings as shown in Table 1 [3].
Fig. 1 Chest radiographs on the first day of endotracheal intubation of four patients with Middle East respiratory syndrome coronavirus
(MERS‐CoV) pneumonia
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ferentiate MERS‐CoV infection from other causes of
respiratory infection. Diagnosis is, therefore, based on
molecular testing by real‐time reverse‐transcription poly-
merase chain reaction (rRT‐PCR) for two sites in theTable 1 Interim case definitions for Middle East respiratory
syndrome coronavirus (MERS‐CoV) infection (as of 14 July 2015) [3]
Probable case An acute respiratory illness with fever and clinical,
radiological, or histopathological evidence of
pulmonary involvement
AND
Direct epidemiologic link with a confirmed
MERS‐CoV case
AND
MERS‐CoV testing is unavailable, negative on a
single inadequate specimen or inconclusive
An acute respiratory illness with fever and clinical,
radiological, or histopathological evidence of
pulmonary involvement
AND
The person lives in or has travelled to Middle
Eastern countries or countries where MERS‐CoV
is known to be circulating in dromedary camels
or where human MERS‐CoV infections have
recently occurred
AND
MERS‐CoV testing is inconclusive
An acute febrile respiratory illness of any severity
AND
Direct epidemiologic link with a confirmed
MERS‐CoV case
AND
MERS‐CoV testing is inconclusive
Confirmed case A person with laboratory‐confirmed MERS‐CoV
infection irrespective of clinical signs and symptomsvirus genome: the upstream E protein (upE) for screen-
ing and the open reading frame (ORF) 1a or 1b for con-
firmation [28]. Lower respiratory tract specimens have a
higher sensitivity than upper respiratory tract specimens
for detecting MERS‐CoV [29]. The success of rRT‐PCR
testing depends on the experience and expertise of la-
boratory personnel, avoidance of contamination and the
type and specimen condition. Gene sequencing targeting
RdRp (present in all corona viruses) and N (specific
to MERS‐CoV) gene fragments can be used for con-
firmation [28]. MERS‐CoV can be also diagnosed by
seroconversion on two samples two weeks apart. En-
zyme‐linked immunosorbent assay can be used for screen-
ing and immunofluorescence assay (IFA) or neutralization
for confirmation [28]. Several MERS‐CoV‐specific sero-
logic assays have been developed but need validation [28].
The MERS‐CoV virus can be cultured in commonly avail-
able cell lines [28]; however, this requires specialized bio-
safety level 3 laboratories.Management
At present, there is no proven specific therapy for
MERS‐CoV infection. Therefore, the mainstay of man-
agement of critically ill patients with MERS‐CoV in-
fection is supportive evidence‐based care. Admission
to the ICU is frequently required for close monitoring
(e.g., patients with high oxygen requirements) or
organ support. The WHO has issued interim guid-
ance for the management of suspected and confirmed
MERS‐CoV infection [30].
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Because of the risk of transmission within the healthcare
setting, appropriate patient isolation and strict imple-
mentation of infection prevention and control measures
are crucial in the management of MERS‐CoV cases. For
suspected cases, the WHO recommends droplet and
contact precautions [30]. When performing an aerosol
generating procedure (e.g., aspiration or open suctioning
of respiratory tract, intubation, bronchoscopy, cardiopul-
monary resuscitation) airborne precautions should be
additionally applied [30]. The Centers for Disease
Control and Prevention (CDC) recommends that droplet
precautions should be added to standard precautions
when providing care to all patients with symptoms of
acute respiratory infection and that a suspected or con-
firmed MERS‐CoV case should be isolated in an airborne
infection isolation room that is constructed and main-
tained according to current guidelines [31]. If such a
room is not available, the patient should be transferred
as soon as is feasible to a facility where one is available
[31]. Until transfer, the patient should wear a facemask
and should be isolated in a room with the door closed
[31]. Healthcare workers should adhere to standard con-
tact and airborne precautions. Hand hygiene should be
performed appropriately and personal protective equip-
ment, including respirators, should be applied correctly
[31]. In addition, visitation should be restricted and
controlled [31]. Hospitals should also develop protocols
to be ready for a potential increase in the need to iso-
late patients with suspected or confirmed MERS‐Cov
infection.
Management of respiratory failure
Early supportive management includes supplemental
oxygen for hypoxemia, respiratory distress and shock
and early invasive mechanical ventilation for significant
respiratory distress or persistent hypoxemia [30]. Pa-
tients with acute respiratory distress syndrome (ARDS)
should receive evidence‐based care that includes a lung‐
protective ventilation strategy [32]: targeting a tidal
volume of 6 ml/kg of predicted body weight, a plateau
airway pressure ≤ 30 cmH2O and SpO2 88–93 % or
PaO2 55–80 mmHg. Moderate to severe ARDS cases
(PaO2:FiO2 < 150 mmHg) are candidates for early prone
positioning [33] and early neuromuscular blockade for
48 h [34]. Proning is recommended within 36 h of
ARDS onset for at least 16 h, since this approach was
associated with reduced mortality compared with
managing patients in the supine position [33]. A 48‐h
infusion of intravenous cisatracurium within 48 h of
ARDS onset has also been associated with reduced
mortality compared with placebo [34]. Extracorporeal
membrane oxygenation (ECMO) is an option for pa-
tients with refractory hypoxemia [35, 36], and has beensuccessfully used in young patients with severe H1N1 in-
fluenza with refractory hypoxemia [36] as well as in
MERS‐CoV patients [11]. Systematic corticosteroids
should generally be avoided unless indicated for other
established reasons [30]. The effect of corticosteroids
on the outcome of MERS‐CoV patients is unknown;
however, corticosteroid use has been associated with
increased morbidity in patients with SARS‐CoV and
severe influenza [37, 38].
High‐flow oxygen, non‐invasive ventilation and high‐
frequency oscillatory ventilation should probably be
avoided or used with caution in MERS patients because
of the potential to generate aerosols and lack of effect-
iveness in patients with ARDS [39]. A systematic review
found that the following procedures were associated
with an increased risk of acute respiratory infection
transmission to healthcare workers through aerosol‐
generation: endotracheal intubation, non‐invasive ven-
tilation, tracheotomy, and manual ventilation [39].
Strict infection prevention practices should, therefore,
be employed when these interventions are performed.
Management of acute kidney injury
Conservative fluid management is advocated especially
in the presence of hypoxemia and the absence of
shock. When renal replacement therapy (RRT) should
be started in patients with AKI is controversial. How-
ever, the presence of fluid overload at the start of
RRT has been associated with a worse outcome [40].
Starting ultrafiltration at lower degrees of fluid over-
load and early targeting of a negative balance may be
beneficial [41, 42].
Feeding
Early trophic feeding for 7 days in ARDS patients [43]
and permissive underfeeding for up to 14 days in mech-
anically ventilated patients [44] have been shown to be
equivalent to target feeding for most outcomes including
survival. Underfeeding may be preferred for patients in
the prone position.
Specific therapies
To date, there is no effective specific treatment for
MERS‐CoV infection. Data on ribavirin, interferon, and
convalescent plasma are limited [21]. A study in rhesus
macaques found that a combination of interferon‐α2b
and ribavirin was associated with a reduction in MERS‐
CoV replication and improved outcome [45]. Clinical
studies on combined ribavirin and interferon showed in-
consistent results [46]. Convalescent sera from patients
who have recovered may be useful. A post‐hoc meta‐
analysis of 32 studies on SARS‐CoV and severe influenza
found reduced mortality after antibody treatment com-
pared with placebo or no treatment (pooled OR 0.25,
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or very low quality [47]. Three studies from separate
laboratories have reported the development of fully hu-
man neutralizing monoclonal antibodies against MERS‐
CoV but no clinical data are currently available [48].
Repurposed commonly‐used drugs, such as statins, my-
cophenolic acid, and anti‐tumor necrosis factor agents,
which have potential anti‐inflammatory or antiviral ef-
fects against MERS‐CoV and at the same time an excel-
lent safety record, may be treatment options. However,
these drugs are not recommended for clinical use out-
side clinical trials [49]. There are no currently licensed
MERS‐CoV vaccines; however, work is ongoing to de-
velop effective vaccines [50].
Outcomes
The overall case fatality rate of MERS‐CoV infection
is ~ 35 % [3]. However, the mortality rate of patients
with severe illness requiring critical care is higher
(58–84 %) [19, 22, 26]. Requirement for ICU admission
for hospitalized patients is frequent (45–70 %) [19, 22]. In
an observational study, 41 out of 49 (84 %) cases requiring
ICU admission died, with 33 (78.6 %) having a pro-
gressive disease course until death [19]. In a multivar-
iable regression analysis, only the presence of a
concomitant infection (OR 14.13, 95 % CI 1.58–
126.09) and a low serum albumin (OR 6.31, 95 % CI
1.24–31.90) were associated with the need for ICU
admission [19]. The multivariable analysis showed
age ≥ 65 years to be the only independent risk factor
for increased mortality (OR 4.39, 95 % CI 2.13–9.05)
[19]. AKI (41 %), hepatic dysfunction (31 %) and car-
diac arrhythmias (16 %), such as tachyarrhythmias
and severe bradycardia requiring temporary pace-
maker insertion, were common complications [19].
Another observational study of 12 critically ill cases
found that barotrauma occurred in 17 %, vasopressors
were needed in 92 % and RRT was performed in
58 % [26]. The median time from onset of symptoms
to intubation was 4.5 days (range 0–33 days). The median
ICU and hospital lengths of stay were 30 (7–104) days and
41 (8–96) days, respectively, and 25 % of patients had a
tracheostomy [26]. The 28‐day and 90‐day mortality rates
were 42 and 58 %, respectively [26].
It should be noted that the mortality of MERS‐CoV
cases during the Korean outbreak (May–July 2015) was
only 19 % compared with ~ 42 % in Saudi Arabia (as at
Sept 11, 2015) [3]. However, the composition of the
two cohorts was different in the relative percentages
of asymptomatic and mildly symptomatic cases. The
Korean healthcare authorities applied widespread screen-
ing and intensified public health measures, such as contact
tracing, quarantine and isolation of suspected cases and
all contacts for at least 14 days [3]. The identification ofasymptomatic or mildly symptomatic patients and differ-
ences in patient characteristics, such as comorbid condi-
tions, may have led to an overall lower mortality rate in
Korea.Conclusions
More than three years after its identification, MERS‐
CoV remains a major global threat. Infection with
MERS‐CoV is frequently severe and associated with sig-
nificant morbidity and mortality. Although our under-
standing of this virus and its disease continues to evolve,
large knowledge gaps remain. The Arabian Peninsula re-
mains the most affected region, but there is concern
about the spread of this virus to other countries and glo-
bally. Until zoonotic transfer of the virus from animals
to humans is stopped, the risk of additional domestic
and perhaps international outbreaks persists. Moreover,
there is an urgent need for larger epidemiologic and out-
come studies and randomized controlled trials examin-
ing different therapeutic interventions. Collaboration
between international health authorities and research
centers is necessary and is crucial to achieve these goals.
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